הכנסה לפני ניכוי ריבית, מסים ופחת: Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals faces colossal risks due to its dependence on the trials of a single drug, anym001. The company's EBITDA clearly demonstrates current volatility, with the indicator status equal to 0.00. High R&D costs and FDA oversight create significant barriers to entry. However, the lack of alternatives in the therapy of cannabinoid poisoning will ensure the asset generates stable income in the future.

Maximum capacity utilization of Anebulo Pharmaceuticals (ANEB) GMP laboratories for the production of pilot drug batches is directly reflected in the EBITDA trend, capturing the operational efficiency of production. This metric is calculated by stripping profit of the impact of depreciation and taxes, allowing investors to assess the business's real cash flow, although peak values do not preclude subsequent price volatility.